Postural Orthostatic Tachycardia Syndrome Clinical Trial
Official title:
Evaluation of the Compensatory Reserve Index and Psychosocial Factors in Pediatric Autonomic Dysfunction
The investigators aim to study whether the Compensatory Reserve Index (CRI) (an FDA approved device that assesses intravascular volume) can be used to evaluate severity of Postural Orthostatic Tachycardia Syndrome (POTS) and whether the CRI value has a correlation with severity of psychosocial symptoms and functional impairment associated with POTS.
Autonomic dysfunction (or dysautonomia) describes several medical conditions linked to the autonomic nervous system. One of these is Postural Orthostatic Tachycardia Syndrome (POTS). In pediatric populations, symptoms of autonomic dysfunction include an increase in heart rate when standing up (tachycardia), dizziness, nausea, vomiting, fatigue, headaches, abdominal discomfort, and sleep disturbances. POTS is specifically characterized by orthostatic intolerance and a forty beats per minute (bpm) increase in heart rate upon standing. The etiology of POTS is poorly understood, and there is limited literature on the management of POTS in pediatric populations. In the U.S., POTS is estimated to affect 1-3 million people. The ability of the CRI algorithm to accurately distinguish individuals with varying tolerances to reduced central blood volume can be attributed to a unique function of the algorithm, which analyzes and compares the entirety of each waveform in a window of time to trend subtle features that correspond with varying degrees of central volume loss. CRI can also detect vascular changes associated with postural orthostatic tachycardia syndrome. CRI will be evaluated in subjects at supine and standing positions along with traditional orthostatic measures. Following CRI measurements, subjects and their parents will be asked to complete a series of surveys to assess their psychosocial symptoms and functional impairment. The CRI measurement and survey completion will occur over the course of one clinic visit. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05555771 -
Paediatric Syncope in the Emergency Department
|
N/A | |
Recruiting |
NCT05923840 -
Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia
|
N/A | |
Completed |
NCT05633407 -
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
|
Phase 2 | |
Completed |
NCT03930914 -
Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome
|
N/A | |
Recruiting |
NCT00865917 -
Cardiovascular Effects of Selective I(f)-Channel Blockade
|
Phase 2 | |
Recruiting |
NCT05741112 -
The Long COVID-19 Wearable Device Study
|
N/A | |
Recruiting |
NCT05454137 -
A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS
|
N/A | |
Recruiting |
NCT05924646 -
CAlgary SAlt for POTS
|
N/A | |
Enrolling by invitation |
NCT05877534 -
Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study
|
N/A | |
Completed |
NCT01367977 -
Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life
|
||
Recruiting |
NCT04881318 -
Compression Garments in the Community With POTS
|
N/A | |
Recruiting |
NCT06292104 -
Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
|
||
Completed |
NCT02171988 -
Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)
|
Phase 4 | |
Completed |
NCT01563107 -
Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
|
N/A | |
Completed |
NCT01547117 -
Dietary Salt in Postural Tachycardia Syndrome
|
N/A | |
Completed |
NCT01617616 -
Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects
|
N/A | |
Active, not recruiting |
NCT02281097 -
Transdermal Vagal Stimulation for POTS
|
N/A | |
Completed |
NCT00728026 -
Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea
|
N/A | |
Recruiting |
NCT05481177 -
Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort
|
Phase 4 | |
Not yet recruiting |
NCT05914649 -
NC Testing in LC & POTS
|
N/A |